Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2005.04.8322PMID 16622263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized

  2007cited by this paper
• Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?

  2006cited by this paper
• Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.

  2005cited by this paper
• Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.

  2005cited by this paper
• Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.

  2005cited by this paper
• Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)

  2005cited by this paper
• ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer

  2005cited by this paper
• Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patients

  2005cited by this paper
• Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype.

  2005cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.

  2005cited by this paper
• Xrcc3 Induces Cisplatin Resistance by Stimulation of Rad51-Related Recombinational Repair, S-Phase Checkpoint Activation, and Reduced Apoptosis

  2005cited by this paper
• Studying the predictive/prognostic role of thymidylate synthase genotypes in patients with colorectal cancer: Is one polymorphism enough?

  2005cited by this paper
• Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

  2004cited by this paper
• Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity

  2004cited by this paper
• Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.

  2004cited by this paper
• Loss of Heterozygosity at the Thymidylate Synthase (TS) Locus on Chromosome 18 Affects Tumor Response and Survival in Individuals Heterozygous for a 28-bp Polymorphism in the TS Gene

  2004cited by this paper
• A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

  2004cited by this paper
• Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil‐based chemotherapy in advanced colorectal cancer patients

  2004cited by this paper
• Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.

  2004cited by this paper
• Excision repair cross complementing-group 1: gene expression and platinum resistance.

  2004cited by this paper
• Effect of XPD/ERCC2 polymorphisms on chromosome aberration frequencies in smokers and on sensitivity to the mutagenic tobacco‐specific nitrosamine NNK

  2004cited by this paper
• Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy

  2004cited by this paper
• Palliative chemotherapy for advanced gastric cancer.

  2004cited by this paper
• Cancer pharmacogenetics

  2004cited by this paper
• Identifying functional genetic variants in DNA repair pathway using protein conservation analysis.

  2004cited by this paper
• Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.

  2004cited by this paper
• Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.

  2004cited by this paper
• Association of thymidylate synthase polymorphisms with gastric cancer susceptibility

  2004cited by this paper
• Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.

  2004cited by this paper
• XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

  2004cited by this paper
• Association between aryl hydrocarbon receptor genotype and survival in soft tissue sarcoma.

  2004cited by this paper
• A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels.

  2004cited by this paper
• The association of thymidylate synthase mRNA expression with its three gene polymorphisms in colorectal cancer.

  2004cited by this paper
• Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.

  2003cited by this paper
• Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells

  2003cited by this paper
• pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5fu)/cpt-11, 5fu/oxaliplatin (oxal), or Cpt-11/oxal therapy for advanced colorectal cancer (crc): Results from an intergroup trial : 1013

  2003cited by this paper
• The role of glutathione-S-transferase in anti-cancer drug resistance

  2003cited by this paper
• Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays.

  2003cited by this paper
• Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.

  2003cited by this paper
• Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.

  2003cited by this paper
• Pharmacogenetics in cancer treatment.

  2003cited by this paper
• Activity Gene Abolishes USF-1 Binding and Alters Transcriptional Thymidylate Synthase Tandem Repeat Polymorphism of the ′ A Novel Single Nucleotide Polymorphism within the 5

  2003cited by this paper
• Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer.

  2002cited by this paper
• Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.

  2002cited by this paper
• Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks

  2002cited by this paper
• Methylenetetrahydrofolate reductase polymorphism is associated with folate pool in gastrointestinal cancer tissue.

  2001cited by this paper
• Mechanisms of resistance to cisplatin.

  2001cited by this paper
• A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

  2001cited by this paper
• Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

  2001cited by this paper
• Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients.

  2001cited by this paper
• A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.

  2001cited by this paper
• Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene.

  2000cited by this paper
• XPD polymorphisms: effects on DNA repair proficiency.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells.

  1999cited by this paper
• Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers.

  1999cited by this paper
• XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency.

  1999cited by this paper
• XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages.

  1998cited by this paper
• Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution.

  1998cited by this paper
• A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies.

  1996cited by this paper
• Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase.

  1995cited by this paper
• Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes.

  1994cited by this paper
• Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues.

  1990cited by this paper
• Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors.

  1989cited by this paper

• The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele‐Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization

  2025cites this paper
• Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications

  2025cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• X-ray cross-complementing family: the bridge linking DNA damage repair and cancer

  2023cites this paper
• Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions

  2022cites this paper
• Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)

  2021cites this paper
• MTHFR polymorphism as a predictive biomarker for gastrointestinal and hematological toxicity in North Indian adenocarcinoma patients

  2021cites this paper
• Prospective Analysis of Pressure Injuries Patients in Relation to Deep Venous Thrombosis

  2019cites this paper
• Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients

  2019cites this paper
• Progress of individualized chemotherapy for gastric carcinoma under the guidance of genetic testing.

  2019cites this paper
• Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers

  2019cites this paper
• Glutathione S-transferases genes variants and chemotherapy efficacy in gastrointestinal cancer patients: a meta-analysis based on 50 pharmacogenetic studies

  2019cites this paper
• A Meta-Analysis: Methylenetetrahydrofolate Reductase C677T Polymorphism in Gastric Cancer Patients Treated with 5-Fu Based Chemotherapy Predicts Serious Hematologic Toxicity but Not Prognosis

  2018cites this paper
• Genomic loss of heterozygosity and survival in the REAL3 trial

  2018cites this paper
• Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis

  2018cites this paper
• Relevance of MTHFR polymorphisms with response to fluoropyrimidine-based chemotherapy in oesophagogastric cancer: a meta-analysis

  2018cites this paper
• Precision medicine in gastric cancer: where are we now?

  2017cites this paper
• MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine

  2017cites this paper
• Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy

  2017cites this paper
• Prognostic significance of vascular endothelial growth factor polymorphisms in colorectal cancer patients

  2017cites this paper
• Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer.

  2017cites this paper
• Evaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphisms on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood.

  2016cites this paper
• Relationship between genetic polymorphisms of methylenetetrahydrofolate reductase and breast cancer chemotherapy response.

  2016cites this paper
• Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis

  2016cites this paper
• Principles of High-Quality Genotyping

  2016cites this paper
• Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports

  2016cites this paper
• Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy

  2016cites this paper
• Abstract. The aim of the present study was to evaluate the effects of thymidylate synthase (TYMS) and excision repair cross-complementing 1 (ERCC1) polymorphisms on chemo- therapeutic efficacy in patients with gastrointestinal tumors using peripheral venous blood. Preoperative peripheral venous bloo

  2016cites this paper
• Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies

  2016cites this paper
• Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients

  2015cites this paper
• Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction

  2015cites this paper
• Excision repair cross-complementary group for chemotherapy efficacy in gastric cancer

  2015cites this paper
• Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy

  2015cites this paper
• Polymorphisms of ERCC1 and XRCC1 predict the overall survival of advanced gastric cancer patients receiving oxaliplatin-based chemotherapy.

  2015cites this paper
• Glutathione S-Transferase Gene Polymorphisms

  2015cites this paper
• Genetic polymorphisms in the microRNA binding‐sites of the thymidylate synthase gene predict risk and survival in gastric cancer

  2015cites this paper
• ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.

  2014cites this paper
• Polymorphism of methylenetetrahydrofolate reductase gene is associated with response to fluorouracil‐based chemotherapy in Chinese patients with gastric cancer

  2014cites this paper
• Oxidative Stress-Related Genetic Polymorphisms Are Associated with the Prognosis of Metastatic Gastric Cancer Patients Treated with Epirubicin, Oxaliplatin and 5-Fluorouracil Combination Chemotherapy

  2014cites this paper
• Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer

  2014cites this paper
• Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?

  2014influential citation
• Association between Polymorphisms in XRCC1 Gene and Treatment Outcomes of Patients with Advanced Gastric Cancer: A Systematic Review and Meta-Analysis

  2014cites this paper
• Quantitative assessment of the associations between DNA repair gene XRCC3 Thr241Met polymorphism and gastric cancer

  2014cites this paper
• A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

  2014cites this paper
• ERCC 1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines

  2014cites this paper
• X‐ray repair cross‐complementing 1 polymorphism and prognosis of platinum‐based chemotherapy in gastric and colorectal cancer: A meta‐analysis

  2014influential citation
• Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis.

  2014cites this paper
• Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

  2014cites this paper
• Association of +405C>G and +936C>T polymorphisms of the vascular endothelial growth factor gene with sporadic breast cancer in North Indians.

  2014cites this paper
• Nucleotide excision repair related gene polymorphisms and genetic susceptibility, chemotherapeutic sensitivity and prognosis of gastric cancer.

  2014cites this paper
• Pharmacogenomics and Cancer Therapy: Somatic and Germline Polymorphisms

  2014cites this paper
• Molecular genetics of gastric adenocarcinoma in clinical practice

  2014cites this paper
• Polymorphisms in Genes of Drug Targets and Metabolism

  2014cites this paper
• rahydrofolate reductase (MTHFR) and reduced folate carrier (SLC19A1) gene polymorphisms and the treatment efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Advanced NSCLC patients received pemetrexed and cisplatin every three weeks. Polymorphisms in the TS, MT

  2013cites this paper
• Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

  2013cites this paper
• Pharmacogenomics and Personalized Medicine for Cancer

  2013cites this paper
• Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC

  2013cites this paper
• Association of vascular endothelial growth factor (VEGF) gene polymorphism and increased serum VEGF concentration with pancreatic adenocarcinoma.

  2013cites this paper
• Polymorphism of TS 3′-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel

  2013cites this paper
• Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy

  2013cites this paper
• A pilot pharmacogenomics study examining the influence of cytotoxic and metabolising genetic polymorphisms on chemotherapy toxicity and outcome in osteosarcoma

  2013influential citation
• Gastric cancer pharmacogenetics: progress or old tripe?

  2013cites this paper
• Cancer Pharmacogenomics

  2012cites this paper
• Locally Advanced and Metastatic Gastric Cancer

  2012cites this paper
• Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review

  2012influential citation
• DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy

  2012cites this paper
• Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

  2012cites this paper
• Prediction role of seven SNPs of DNA repair genes for survival of gastric cancer patients receiving chemotherapy.

  2012cites this paper
• Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.

  2012cites this paper
• Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma

  2012cites this paper
• Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.

  2011cites this paper
• Genetic changes in melanoma progression

  2011cites this paper
• Estudio de polimorfismos de genes reparadores del ADN en cáncer de mama

  2011cites this paper
• Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels

  2011cites this paper
• Translational Medicine and Reliability of Single-Nucleotide Polymorphism Studies: Can We Believe in SNP Reports or Not?

  2011cites this paper
• Association of the VEGF 936C>T Polymorphism with FDG Uptake, Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the Esophagogastric Junction

  2011cites this paper
• Association Between XRCC1 ARG399GLN and P53 ARG72PRO Polymorphisms and the Risk of Gastric and Colorectal Cancer in Turkish Population

  2011cites this paper
• Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma.

  2011cites this paper
• 5 Current insights in the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anti-cancer drugs

  2011cites this paper
• Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.

  2011cites this paper
• Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

  2011cites this paper
• BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin

  2010cites this paper
• Interaction between glutathione-S-transferase polymorphisms, smoking habit, and HPV infection in cervical cancer risk

  2010influential citation
• Pharmacogenetics of advanced colorectal cancer treatment

  2010cites this paper
• A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma

  2010cites this paper
• Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer

  2010cites this paper
• ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.

  2010cites this paper
• Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.

  2010cites this paper
• A metabonomic approach to chemosensitivity prediction of cisplatin plus 5‐fluorouracil in a human xenograft model of gastric cancer

  2010cites this paper
• Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.

  2010cites this paper
• MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis.

  2009cites this paper
• Glutathione S-transferase P1 gene polymorphism associated with gastric cancer among Caucasians.

  2009cites this paper
• Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

  2009influential citation
• CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.

  2009cites this paper
• Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy

  2009influential citation
• ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX‐4 treatment in Asian patients with metastatic colorectal carcinoma

  2009cites this paper
• Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.

  2009cites this paper
• Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment

  2009cites this paper
• Pharmacogenetics in chemotherapy of colorectal cancer.

  2009cites this paper
• Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.

  2009cites this paper